PD-1 jointly developed by Yuheng pharmaceutical and Yaoming biology was approved for listing
Financial Associated Press, August 30 - on August 30, the official website of the State Food and drug administration showed that the anti-PD-1 whole person innovative antibody drug cyprimab (gls-010) jointly developed by Yuheng pharmaceutical / Yaoming biology has been approved by nmpa to be listed for the treatment of patients with recurrent or refractory classic Hodgkin's lymphoma (R / R CHL) above the second line. This is the sixth domestic PD-1 mAb approved by nmpa.
This text is a result of machine translation.
Related companies：
In depth
Apr 22, 2021 03:11 PM
Research
Consumer Staples, Technology, HealthcareWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Aug 09, 2020 12:23 AM
Briefing Oct 04, 2021 09:52 AM
· Healthcare
Hong Kong Pharmaceutical stocks fell sharply, Fosun Pharmaceutical fell more than 20% and Yaoming biology fell more than 7%.
Insight
Briefing Jul 21, 2021 03:11 PM
The latest position of Qu Yang, fund manager of Qianhai open source: Hong Kong stocks redistributed, Tencent holdings and BYD holdings increased
Briefing Jul 21, 2021 08:05 AM
· Healthcare
Notice: the National Health Commission will hold a press conference on China's hierarchical diagnosis and treatment system and system construction
Briefing Updated 2 hours ago
· Healthcare
What if antibiotics pollute the environment? Chinese scholars put forward solutions
See more
Read next
In depth
In depth
Insight
Consumer Staples, Consumer Discretionary
Medium Power: Reshaped China Consumption
Oct 14, 2021 11:09 AM
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.